Current Environment: Production

Medical Services

Programs & Services

Languages

  • English

Certifications

  • American Board of Pediatrics (General)

Publications

  1. Lymphoid malignancies in patients with Shwachman-Diamond syndrome. Blood. 2025 May 22; 145(21):2528-2532. View Abstract

  2. X-linked sideroblastic anemia in females. Blood. 2025 Apr 03; 145(14):1583-1587. View Abstract

  3. Primary CNS histiocytic sarcoma: Two case reports highlighting a novel MIGA2::BRAF gene fusion and genome-wide DNA methylation profiling results. J Neuropathol Exp Neurol. 2024 Oct 01; 83(10):882-886. View Abstract

  4. Epithelioid Fibrous Histiocytoma Is on a Continuum With Superficial ALK-rearranged Myxoid Spindle Cell Neoplasm: A Clinicopathologic Series of 35 Cases Including Alternate RET and NTRK3 Fusions. Am J Surg Pathol. 2024 Sep 27. View Abstract

  5. Acute Promyelocytic Leukemia With Torque Teno Mini Virus::RARA Fusion: An Approach to Screening and Diagnosis. Mod Pathol. 2024 Jul; 37(7):100509. View Abstract

  6. Vascular, adipose tissue, and/or calyceal invasion in clear cell tubulopapillary renal cell tumour: potentially problematic diagnostic scenarios. Histopathology. 2024 Jun; 84(7):1167-1177. View Abstract

  7. IKZF1 Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia. Biomedicines. 2024 Jan 01; 12(1). View Abstract

  8. ETV6 fusions from insertions of exons 3-5 in pediatric hematologic malignancies. Haematologica. 2023 12 01; 108(12):3471-3476. View Abstract

  9. Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. Clin Cancer Res. 2023 11 14; 29(22):4613-4626. View Abstract

  10. Cutaneous Manifestations of Myeloid Neoplasms Exhibit Broad and Divergent Morphologic and Immunophenotypic Features but Share Ancestral Clonal Mutations With Bone Marrow. Mod Pathol. 2024 Jan; 37(1):100352. View Abstract

  11. FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged =60 years. Blood Adv. 2023 09 26; 7(18):5354-5358. View Abstract

  12. Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study. J Clin Oncol. 2023 Oct 01; 41(28):4497-4510. View Abstract

  13. Outlier Expression of Isoforms by Targeted or Total RNA Sequencing Identifies Clinically Significant Genomic Variants in Hematolymphoid Tumors. J Mol Diagn. 2023 09; 25(9):665-681. View Abstract

  14. Concordance of MTOR Pathway Mutations and the Diagnosis of Renal Low-Grade Oncocytic Tumor (LOT). Int J Surg Pathol. 2024 Apr; 32(2):316-330. View Abstract

  15. Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. JCO Precis Oncol. 2022 11; 6:e2200390. View Abstract

  16. Clinicopathologic and molecular spectrum of testicular sex cord-stromal tumors not amenable to specific histopathologic subclassification. Mod Pathol. 2022 12; 35(12):1944-1954. View Abstract

  17. Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer. JCO Precis Oncol. 2022 Aug; 6:e2200329. View Abstract

  18. Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes. Blood Adv. 2022 07 26; 6(14):4236-4240. View Abstract

  19. Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML. Blood. 2022 06 16; 139(24):3546-3557. View Abstract

  20. Histopathological and genetic features of mismatch repair-deficient high-grade prostate cancer. Histopathology. 2022 Jun; 80(7):1050-1060. View Abstract

  21. Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy. Oncologist. 2022 03 04; 27(2):82-86. View Abstract

  22. Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis. Clin Cancer Res. 2022 Mar 01; 28(5):928-938. View Abstract

  23. A Clinicopathological and Molecular Analysis of Fumarate Hydratase (FH)-deficient Renal Cell Carcinomas with Heterogeneous Loss of FH Expression. Int J Surg Pathol. 2022 Sep; 30(6):606-615. View Abstract

  24. Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer. J Pathol. 2021 12; 255(4):425-437. View Abstract

  25. The Differential Diagnosis of Medullary-Based Renal Masses. Arch Pathol Lab Med. 2021 09 01; 145(9):1148-1170. View Abstract

  26. Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer. Prostate. 2021 11; 81(15):1159-1171. View Abstract

  27. Assessment of BCOR Internal Tandem Duplications in Pediatric Cancers by Targeted RNA Sequencing. J Mol Diagn. 2021 10; 23(10):1269-1278. View Abstract

  28. Targeted Informatics for Optimal Detection, Characterization, and Quantification of FLT3 Internal Tandem Duplications Across Multiple Next-Generation Sequencing Platforms. J Mol Diagn. 2020 09; 22(9):1162-1178. View Abstract

  29. Use of Deep Learning to Develop and Analyze Computational Hematoxylin and Eosin Staining of Prostate Core Biopsy Images for Tumor Diagnosis. JAMA Netw Open. 2020 05 01; 3(5):e205111. View Abstract

  30. INSM1 expression in a subset of thoracic malignancies and small round cell tumors: rare potential pitfalls for small cell carcinoma. Mod Pathol. 2020 08; 33(8):1571-1580. View Abstract

  31. Delayed Relapse of Paracoccidioidomycosis in the Central Nervous System: A Case Report. Open Forum Infect Dis. 2020 Apr; 7(4):ofaa077. View Abstract

  32. Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement. Blood Adv. 2020 01 14; 4(1):106-111. View Abstract

  33. A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma. Thyroid. 2019 11; 29(11):1704-1707. View Abstract

  34. Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma. Int J Cancer. 2019 12 15; 145(12):3453-3461. View Abstract

  35. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. Gigascience. 2018 06 01; 7(6). View Abstract

  36. Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. Clin Cancer Res. 2018 08 15; 24(16):3908-3916. View Abstract

  37. Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. Am J Pathol. 2018 06; 188(6):1478-1485. View Abstract

  38. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma. BMC Cancer. 2017 Nov 13; 17(1):759. View Abstract

  39. AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination. Nat Commun. 2017 07 26; 8(1):142. View Abstract

  40. Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer. Clin Cancer Res. 2016 Sep 15; 22(18):4651-63. View Abstract

  41. Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens. Am J Clin Pathol. 2016 May; 145(5):696-702. View Abstract

  42. A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AML. Mol Diagn Ther. 2015 Dec; 19(6):409-17. View Abstract

  43. Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. Clin Cancer Res. 2015 Dec 15; 21(24):5619-29. View Abstract

  44. The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell Rep. 2015 Aug 11; 12(6):922-36. View Abstract

  45. Diversity of miRNAs, siRNAs, and piRNAs across 25 Drosophila cell lines. Genome Res. 2014 Jul; 24(7):1236-50. View Abstract
BESbswy